Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-04-24 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
未来三年股东分红回报规划（2020-2022）
Notice of Dividend Amount Classification · 95% confidence The document is a detailed statement from the board of Shenzhen BGI Genomics Co., Ltd. regarding the company's shareholder dividend return plan for the years 2020-2022. It outlines principles, conditions, procedures, and mechanisms for profit distribution and dividend policy. It references regulatory guidelines from the China Securities Regulatory Commission and the company's articles of association. The document is not a financial report, earnings release, or audit report, nor is it a brief announcement or a presentation. It is a formal policy document issued by the board concerning dividends and shareholder returns over a multi-year period. This fits best under the category of a Notice of Dividend Amount (DIV), as it details the dividend policy and plans for shareholder returns, even though it is a multi-year plan rather than a single dividend announcement. The document length is 2671 characters, which is substantive but not a full financial report. Therefore, the classification is DIV with high confidence.
2020-04-24 Chinese
关于使用暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle own funds for cash management. It details the board meeting approval, investment purpose, investment products, risk control measures, and opinions from independent directors, supervisory board, and the sponsoring institution. The document is a formal disclosure about a financing or capital management activity, specifically the use of idle funds for low-risk financial products. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and investment of idle funds.
2020-04-24 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding a change in accounting policies. It details the adoption of new accounting standards issued by the Ministry of Finance, including a new revenue recognition standard and revised financial statement formats. The document includes explanations of the changes, their impact on the company, and approvals from the board, independent directors, and supervisory board. It does not contain actual financial statements or comprehensive financial data but rather informs stakeholders about the policy change and its rationale. The document length is 3336 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting policy changes without substantive financial data or full report content.
2020-04-24 Chinese
2019年年度报告
Annual Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2019 年年度报告全文" which translates to "BGI Genomics Co., Ltd. 2019 Annual Report Full Text." It contains detailed sections such as company overview, financial data, governance, and management information. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of financial data, company information, and detailed analysis confirms this is the full annual report for the fiscal year 2019. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2020-04-24 Chinese
2019社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled "深圳华大基因股份有限公司2019 年度社会责任报告" which translates to "BGI Genomics Co., Ltd. 2019 Social Responsibility Report." The content extensively covers the company's environmental, social, and governance (ESG) practices, including detailed sections on social responsibility, community engagement, environmental protection, employee welfare, and contributions to public health such as COVID-19 response efforts. It references ESG frameworks like the UN Sustainable Development Goals and ISO 26000. There is no indication that this is a financial report, audit, or regulatory filing. The document is comprehensive and over 15,000 characters, indicating it is the full report rather than an announcement. Therefore, the document fits the category of Environmental & Social Information (Code: SR).
2020-04-24 Chinese
中信证券股份有限公司关于公司使用暂时闲置自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s use of temporarily idle own funds for cash management. It includes descriptions of investment purpose, types, limits, decision procedures, risk control measures, and approvals from the board, independent directors, and supervisory board. The document is a formal verification and due diligence report by the sponsor institution, not a financial report or earnings release. It does not contain financial statements or earnings data but rather an audit-like opinion on a specific corporate action related to cash management. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report on a specific matter, excluding full annual or interim reports. The document length is 3096 characters, which is sufficient for a detailed audit opinion but not a full annual or interim report. Therefore, the classification is AR with high confidence. FY 2020
2020-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.